Phase I Study Combining an Anti-SEMA4D Antibody VX15/2503 With Checkpoint Inhibitors for Patients With Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 25 Mar 2021 Status changed from active, no longer recruiting to discontinued.
- 23 Feb 2021 Planned End Date changed from 1 Dec 2021 to 28 Feb 2022.
- 23 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 28 Feb 2021.